Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This patent grant represents a significant milestone for Greenland Mines’ biotech division, which focuses on developing therapies for devastating neurological conditions. The Klotho gene has been linked to longevity and cognitive function, and enhancing its expression through gene therapy could offer new treatment avenues for diseases that currently have limited options. The company’s ability to secure patent protection in multiple jurisdictions, including Canada, strengthens its competitive position and potential for future partnerships or licensing deals.
Greenland Mines is a Nasdaq-listed company with two operating divisions: mining and biotech. Its mining division focuses on the Skaergaard Project in Greenland and the Sarfartoq rare earths project, while its biotech division advances Klotho-based therapies. The company’s strategy centers on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision.
For more information, visit the company’s newsroom at https://ibn.fm/GRML. The full press release is available at https://ibn.fm/x2pHA.
